#None #Harbour BioMed #antibody therapeutics #Dhavalkumar Patel

Harbour BioMed Welcomes Dr. Dhavalkumar Patel as Scientific Advisor

Harbour BioMed, a prominent player in the global biopharmaceutical landscape, has officially named Dr. Dhavalkumar Patel as its new Scientific Advisor, a decision that underscores its commitment to advancing novel therapeutic development in the fields of immunology and oncology. This appointment comes at a critical time for the company, as it seeks to expand its portfolio of cutting-edge antibody therapies.

Dr. Patel is recognized for his remarkable two-decade career, during which he has contributed significantly to therapeutic innovation across both industry and academia. He currently holds the position of Executive Vice President and Chief Scientific Officer at Sana Biotechnology, where he has been instrumental in steering significant advancements in biopharmaceuticals since 2024.

Prior to his tenure at Sana, Dr. Patel served as Executive Vice President and Chief Scientific Officer at UCB, where his leadership played a vital role in the development and registration of several key therapies, including bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®), and zilucoplan (Zilbrysq®). His prior experience at Novartis further enriched his expertise, as he was pivotal in advancing multiple therapies such as secukinumab (Cosentyx®) and fingolimod (Gilenya®). His history also includes a significant academic career as an eminent professor, leading major research initiatives at the University of North Carolina and Duke University.

In his new role at Harbour BioMed, Dr. Patel will provide critical strategic insight, leveraging his extensive experience to guide the company’s ambitions in building a comprehensive immunology pipeline.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, expressed excitement about Dr. Patel's appointment, highlighting that his deep understanding of immunological science combined with successful drug development provides a rich resource for the company. “We are eager to harness his insights as we continue to develop our innovative antibody programs,” Wang stated.

Expressing his enthusiasm about joining Harbour BioMed, Dr. Patel remarked, “I am honored to be part of Harbour BioMed. The company has cultivated an impressive portfolio of antibody candidates targeting critical immune pathways. I am looking forward to collaborating closely with the team to accelerate the progression of our programs from early discovery through development to clinical application.”

This strategic move aligns with Harbour BioMed’s overarching mission to discover and develop novel antibody therapeutics across various diseases. In particular, their proprietary technology, known as Harbour Mice®, is a hallmark of the company’s innovative approach, enabling them to produce fully human monoclonal antibodies effectively. With platforms like HBICE® and HCAb PLUSTM, Harbour BioMed is dedicated to pioneering the next generation of therapeutic solutions that could address significant unmet medical needs.

As Harbour BioMed gears up for its next chapter, the addition of Dr. Patel is poised to strengthen its efforts in cultivating a diverse pipeline that not only brings new treatments to market but also enhances patient outcomes across a variety of therapeutic areas. With the biopharmaceutical landscape continually evolving, Harbour BioMed is positioning itself as a leader in antibody therapeutics, particularly in immunology.

For more information about Harbour BioMed and its innovative work, please visit www.harbourbiomed.com.